Please login to the form below

Not currently logged in
Email:
Password:

lung cancer

This page shows the latest lung cancer news and features for those working in and with pharma, biotech and healthcare.

Keytruda monotherapy fails in triple negative breast cancer

Keytruda monotherapy fails in triple negative breast cancer

non-small cell lung cancer, has emboldened Merck &Co. ... It added another new indication in April when it gained FDA approval in combination with Pfizer’s Inlyta for kidney cancer patients.

Latest news

  • Boehringer eyes rare disease use for respiratory blockbuster Boehringer eyes rare disease use for respiratory blockbuster

    Nintedanib – sold as Ofev for idiopathic pulmonary fibrosis (IPF) and Vargatef for and some types of non-small cell lung cancer (NSCLC) – is one of Boehringer’s most important growth products ... and was filed for interstitial lung disease (ILD) in

  • So far so good for Amgen's much-anticipated KRAS inhibitor So far so good for Amgen's much-anticipated KRAS inhibitor

    The abstract covers 22 patients with KRAS G12C-mutated solid tumours, mainly non-small cell lung cancer (NSCLC) and colorectal cancer, who were enrolled before the data cut-off in the ... December – and pasotuxizumab, a PSMA and CD3-targeting BiTE for

  • Lilly scores FDA okay for Cyramza in liver cancer Lilly scores FDA okay for Cyramza in liver cancer

    Since it first reached the market in 2014, Cyramza has been approved to treat oesophageal cancer, gastric cancer after chemotherapy, non-small cell lung cancer (NSCLC) and colorectal cancer, and has ... result of a switch to immuno-oncology drugs in

  • Grail’s multi-cancer blood test gets FDA breakthrough status Grail’s multi-cancer blood test gets FDA breakthrough status

    The company first made waves with its tests last year, when it announced it will deploy its lung cancer-detecting blood test into 50, 000 people in the UK. ... However, it isn't alone in its pursuit of developing new cancer diagnostics.

  • AZ invests more in IO with Transgene oncolytic virus deal AZ invests more in IO with Transgene oncolytic virus deal

    oncology. The firm’s lead IO therapy Imfinzi has recently gained FDA and European approval in an important niche setting in lung cancer, but it’s otherwise an also-ran compared ... to Merck &Co’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq,

More from news
Approximately 98 fully matching, plus 722 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    Back in 2016, Chinese scientists led by oncologist Lu You at Sichuan University in Chengdu, injected CRISPR-modified cells into a patient with a form of lung cancer at the West ... hope was that - without the brake of PD-1 – the edited cells would

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... April. Naturally Merck &Co isn’t confining itself to dominance in lung cancer.

  • China’s clinical trial shake-up China’s clinical trial shake-up

    For example, around 40% of new lung cancer diagnoses worldwide are in China. ... Once seen as a manufacturer of generics rather than a developer of innovative drugs, China is now involved in half of all enrolling cancer trials of CAR-T cell therapies.

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    of this include recent deals on CAR-T therapies, plus a new expansion in the use of Keytruda in lung cancer, announced late last year. ... Value assessment. More and faster NICE appraisals for new medicines including speeding up the appraisal of

  • Is China ready for a pharmaceutical gold rush?

    With most lung cancer patients already at an advanced stage when diagnosed, prolonging survival is an important goal. ... According to Chinese Government figures, there are about 781, 000 new lung cancer diagnoses in the country every year.

More from intelligence
Approximately 1 fully matching, plus 48 partially matching documents found.

Latest appointments

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • Merck appoints ex-Pfizer exec as global head of oncology Merck appoints ex-Pfizer exec as global head of oncology

    lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.

  • Merck appoints new senior vice president Merck appoints new senior vice president

    Radvanyi will focus on leading the discovery of oncology therapies that leverage the natural ability of the body's immune system to fight cancer, as well as identifying biomarkers with the ... indications including lung, cervical and breast cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics